Cargando…
Targeted treatment of severe vascular malformations harboring PIK3CA and TEK mutations with alpelisib is highly effective with limited toxicity
This was a prospective cohort study of eighteen patients with large and debilitating vascular malformations with one or more major systemic complications. In all patients, we discovered activating alterations in either TEK or PIK3CA. Based on these findings, targeted treatment using the PI3K inhibit...
Autores principales: | Sterba, Martin, Pokorna, Petra, Faberova, Renata, Pinkova, Blanka, Skotakova, Jarmila, Seehofnerova, Anna, Blatny, Jan, Janigova, Lucia, Koskova, Olga, Palova, Hana, Mahdal, Michal, Pazourek, Lukas, Jabandziev, Petr, Slaby, Ondrej, Mudry, Peter, Sterba, Jaroslav |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10307862/ https://www.ncbi.nlm.nih.gov/pubmed/37380669 http://dx.doi.org/10.1038/s41598-023-37468-4 |
Ejemplares similares
-
Effects of Sunitinib and Other Kinase Inhibitors on Cells Harboring a PDGFRB Mutation Associated with Infantile Myofibromatosis
por: Sramek, Martin, et al.
Publicado: (2018) -
Case report: rapid and durable response to PDGFR targeted therapy in a child with refractory multiple infantile myofibromatosis and a heterozygous germline mutation of the PDGFRB gene
por: Mudry, Peter, et al.
Publicado: (2017) -
Spindle Cell Hemangioma and Atypically Localized Juxtaglomerular Cell Tumor in a Patient with Hereditary BRIP1 Mutation: A Case Report
por: Papez, Jan, et al.
Publicado: (2021) -
Improved osteosarcoma survival with addition of mifamurtide to conventional chemotherapy – Observational prospective single institution analysis
por: Múdry, Peter, et al.
Publicado: (2021) -
Minimal Residual Disease–Guided Intermittent Dosing in Patients With Cancer: Successful Treatment of Chemoresistant Anaplastic Large Cell Lymphoma Using Intermittent Lorlatinib Dosing
por: Pokorna, Petra, et al.
Publicado: (2022)